title: Soy protein and isoflavones influence adiposity and development of metabolic syndrome in the obese male ZDF rat.
abstract: OBJECTIVE
  Previously, we demonstrated that soy protein ameliorates the diabetic phenotype in several rodent models of obesity and metabolic syndrome (MS). This study was designed to further elucidate factors related to adiposity, glycemic control, and renal function in male Zucker Diabetic Fatty (ZDF/Lepr(fa)) rats.
  
  
  METHODS
  Animals were randomly assigned to one of four diets: control, casein (C); low isoflavone (LIS) soy protein; high isoflavone (HIS) soy protein, or casein + rosiglitazone (CR) for 11 weeks. At sacrifice, physiological, biochemical, and molecular parameters were determined.
  
  
  RESULTS
  Body weight and total adiposity were higher in LIS and CR diet groups despite lower food intake. Additionally, these animals exhibited differential regulation of adipose-specific proteins (PPAR-gamma and GLUT4) and enzyme activity (FAS and GPDH). HIS-fed animals had reduced total and liver adiposity. Glycemic control was prolonged in both soy-based and rosiglitazone (RGZ) groups. Renal dysfunction was significantly reduced in soy-fed and RGZ-treated rodents as demonstrated by lower levels of proteinuria and dilated tubules with proteinaceous casts.
  
  
  CONCLUSIONS
  Collectively, these data provide evidence that soy protein with low or high isoflavone content may have therapeutic significance in reducing severity of diabetes, MS, and renal disease as demonstrated in this preclinical model.
authors.affiliation: Southern Illinois University, Carbondale, IL 62901-4317, USA.
authors.forename: Jeremy
authors.initials: J
authors.lastname: Davis
authors.forename: Allan
authors.initials: A
authors.lastname: Higginbotham
authors.forename: Timothy
authors.initials: T
authors.lastname: O'Connor
authors.forename: Naima
authors.initials: N
authors.lastname: Moustaid-Moussa
authors.forename: Adam
authors.initials: A
authors.lastname: Tebbe
authors.forename: Young-Cheul
authors.initials: YC
authors.lastname: Kim
authors.forename: Kae Won
authors.initials: KW
authors.lastname: Cho
authors.forename: Neil
authors.initials: N
authors.lastname: Shay
authors.forename: Stuart
authors.initials: S
authors.lastname: Adler
authors.forename: Richard
authors.initials: R
authors.lastname: Peterson
authors.forename: William
authors.initials: W
authors.lastname: Banz
mesh_terms: D050154:Adiposity / Q000187:drug effects*; D000818:Animals; D001786:Blood Glucose / Q000187:drug effects; D002364:Caseins / Q000494:pharmacology; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007529:Isoflavones / Q000494:pharmacology*; D007674:Kidney Diseases / Q000517:prevention & control; D008099:Liver / Q000187:drug effects; D008297:Male; D024821:Metabolic Syndrome / Q000178:diet therapy* / Q000209:etiology; D008894:Milk Proteins / Q000494:pharmacology; D009765:Obesity / Q000150:complications*; D011507:Proteinuria / Q000517:prevention & control; D051381:Rats; D011919:Rats, Inbred Strains; D000077154:Rosiglitazone; D030262:Soybean Proteins / Q000008:administration & dosage*; D045162:Thiazolidinediones / Q000494:pharmacology
chemical_list: D001786:Blood Glucose; D002364:Caseins; D007004:Hypoglycemic Agents; D007529:Isoflavones; D008894:Milk Proteins; D030262:Soybean Proteins; D045162:Thiazolidinediones; D000077154:Rosiglitazone